This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from July 2025. ICYMI, Express Scripts will boot the reference products from its 2026 formulary, but will cling to its biosimilar pricing double standard. --- The 2025 launch of biosimilars to Johnson & Johnson’s Stelara (ustekinumab) marks another turning point in pharmacy benefit dyn...| Drug Channels
After multiple years of mandated disclosure of negotiated hospital-insurer rates, those of us who follow the buy-and-bill channel might have expected transparency to reduce drug price variability, lower hospital markups, and accelerate adoption of lower-cost biosimilars. Alas, that’s not what the latest data reveal. DCI’s analysis of four national commercial insurers—Aetna, Anthem, Cigna, and UnitedHealthcare—and 26 hospitals found that: Hospitals still earn significant markups over a...| Drug Channels